QPPV.COM KNOWLEDGE ASSESSMENT

Sacituzumab Govitecan: Mechanism, Clinical Safety and Pharmacovigilance Knowledge Assessment

Test your understanding of the concepts covered by Sacituzumab govitecan: Mechanism, Clinical Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which statement correctly distinguishes seriousness from expectedness?

A serious event is automatically unexpected An expected event cannot be serious Seriousness concerns regulatory criteria such as hospitalisation or life-threatening course, whereas expectedness is assessed against the applicable reference safety information Both terms are interchangeable assessments based only on event frequency

Question 2 of 10 Which factor should be considered when deciding whether primary G-CSF prophylaxis may be appropriate?

Whether the patient has increased risk of febrile neutropenia Whether the patient has a positive Trop-2 test, which is mandatory Whether diarrhoea has already occurred in every prior cycle Whether the patient received an infusion lasting exactly one hour

Question 3 of 10 A patient develops grade 4 neutropenia two days after the day-8 infusion, with fever and hospitalisation. Which data set is most important for reconstructing the case?

Only the patient's tumour Trop-2 result Only the date on which the adverse event was reported Baseline and nadir ANC, both infusion dates, fever, cultures, antimicrobial treatment, admission and growth-factor use Only the final decision to discontinue treatment

Question 4 of 10 Which statement best describes the relationship between neutropenia and causality in a heavily pretreated patient?

The occurrence after dosing proves the drug was the sole cause Previous chemotherapy, marrow involvement and infection may contribute, so timing supports investigation but does not establish causality Neutropenia cannot be related to the product if the patient has received prior chemotherapy Only a positive UGT1A1*28 result permits attribution

Question 5 of 10 Which monitoring approach is most consistent with the article?

Check blood counts only at the end of each 21-day cycle Use generic ADC thresholds and ignore the product's day-1/day-8 rules Review counts before dosing and more closely after severe neutropenia, febrile neutropenia, dose delays or known reduced UGT1A1 activity Stop monitoring once the first cycle is tolerated

Question 6 of 10 How should homozygosity for UGT1A1*28 be incorporated into a safety assessment?

It proves that any adverse event was caused by sacituzumab govitecan It is irrelevant because UGT1A1 does not affect SN-38 handling It is a vulnerability factor associated with slower SN-38 glucuronidation and increased haematologic toxicity, but does not replace clinical assessment It establishes that treatment was contraindicated in every case

Question 7 of 10 Which statement about Trop-2 testing is supported by the article?

Trop-2 testing is required as a companion diagnostic before treatment A treatment decision proves that the patient's tumour was Trop-2 positive The label does not require Trop-2 testing as a companion diagnostic, so the actual test result should not be inferred Trop-2 status replaces the need to document hormone-receptor and HER2 status

Question 8 of 10 Which documentation best characterises clinically important diarrhoea in a pharmacovigilance case?

The preferred anti-diarrhoeal product name only Stool frequency above baseline, onset and duration, fever or blood, oral intake, hydration, laboratory changes, treatment and infection work-up The patient's age and tumour receptor status only A single statement that diarrhoea was severe

Question 9 of 10 Which information is most relevant when evaluating a possible infusion-related reaction?

Infusion start and stop times, rate, premedication, onset, vital signs, interruption, rescue treatment and subsequent tolerance Only the tumour's receptor phenotype Only the UGT1A1 genotype Only whether the patient later developed alopecia

Question 10 of 10 Why should day-1 and day-8 administrations be recorded separately in an adverse-event case?

Only the day-1 dose contributes to exposure, whereas day 8 is administrative Toxicity may emerge or worsen after either infusion, so temporal attribution and dose modification require both exposure dates The day-8 dose is given in a different treatment cycle Separate recording is needed only for product-quality complaints

QPPV.com

Sacituzumab Govitecan: Mechanism, Clinical Safety and Pharmacovigilance Knowledge Assessment

Cookie Settings